rethinkPeptides Search
Menu
Study breakdown

GLP-1 Drugs for Psoriasis: Emerging Anti-Inflammatory Potential for Skin

evidence
The takeaway

Review of GLP-1 drug emerging therapeutic potential in psoriasis management covers anti-inflammatory mechanisms that may benefit this autoimmune skin disease.

Key finding

Review of GLP-1 drug emerging therapeutic potential in psoriasis management covers anti-inflammatory

What the researchers found

Review of GLP-1 drug emerging therapeutic potential in psoriasis management covers anti-inflammatory mechanisms that may benefit this autoimmune skin disease.

Why it matters

Relevant to peptide therapeutics.

How the study worked

In publication.

What this study cannot tell us

In publication.

How to read the evidence

Based on design.

When this study was published

Published in 2025.

The bigger picture

Advances peptide evidence.

Questions still open

  • Long-term implications?
  • Evidence comparison?
  • Next steps?

Common questions

What does this mean?
Review of GLP-1 drug emerging therapeutic potential in psoriasis management covers anti-inflammatory mechanisms that may benefit this autoimmune skin disease.
How reliable?
Consult publication.

Read the original research

GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management - current evidence and future outlook.

European journal of clinical pharmacology, 81(11), 1569-1581

Citation

Atiquzzaman, Nabiha; Razdolsky, Nicole; Parmar, Mayur S. (2025). GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management - current evidence and future outlook.. European journal of clinical pharmacology, 81(11), 1569-1581. https://doi.org/10.1007/s00228-025-03898-4